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Primary goals of the Hepatitis C Action Plan for Scotland Phase II (May 2008–March 2011) 
were to increase, among persons chronically infected with the hepatitis C (HCV) virus, 
attendance at specialist outpatient clinics and initiation on antiviral therapy. We evaluated 
progress towards these goals by comparing the odds, across time, of (a) first clinic 
attendance within 12 months of HCV diagnosis (n=9,747); and (b) initiation on antiviral 
treatment within 12 months of first attendance (n=5,736). Record-linkage between the 
national HCV diagnosis (1996-2009) and HCV Clinical (1996-2010) databases and logistic 
regression analyses were conducted for both outcomes. For outcome (a), 32% and 45% in the 
respective pre-Phase II (before 1 May 2008) and Phase II periods attended a specialist clinic 
within 12 months of diagnosis; the odds of attendance within 12 months increased over time 
(OR=1.05 per year, 95% CI: 1.04–1.07), but was not significantly greater for persons 
diagnosed with HCV in the Phase II era, compared with the pre-Phase II era (OR=1.1, 95% 
CI: 0.9-1.3), after adjustment for temporal trend. For outcome (b), 13% and 28% were 
initiated on treatment within 12 months of their first clinic attendance in the pre-Phase II 
and Phase II periods, respectively. Higher odds of treatment initiation were associated with 
first clinic attendance in the Phase II (OR=1.9, 95% CI: 1.5-2.4), compared with the pre-Phase 
II era. Results were consistent with a positive impact of the Hepatitis C Action Plan on the 
treatment of chronically-infected individuals, but further monitoring is required to confirm a 
sustained effect. 
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INTRODUCTION  
Infection with the hepatitis C virus (HCV) is a serious public health problem world-
wide, affecting 170 million people according to the WHO. The long natural history of 
chronic HCV infection means that the greatest burden – from life-threatening complications 
such as decompensated cirrhosis and hepatocellular carcinoma – is still to come. Modelling 
work to forecast the future burden indicates that unless identification, management, and 
treatment of chronic cases is vastly improved, the numbers of patients developing end-stage 
liver disease will continue to rise. (1) 
Challenges for chronic HCV patient management along the entire pathway from 
diagnosis to antiviral therapy have been identified;(2-4) and there is much reported 
variability in rates of attendance at specialist hepatitis clinics and treatment uptake.(5,6) 
Previous research, with only a few exceptions, (7) has typically involved relatively small 
cohorts of HCV patients with limited follow-up; large population-based studies are needed 
for assessment of all aspects of HCV patient management, and for evaluation of national 
public health policy initiatives.  
In recognition that HCV represents one of the most serious contemporary public health 
issues in Scotland, the Scottish Health Minister and Chief Medical Officer jointly launched 
the Hepatitis C Action Plan for Scotland in September 2006. Phase 1 of this programme 
(September 2006 to March 2008) was largely an initial evidence-gathering initiative to inform 
proposals for Phase II, but also aimed to improve awareness of HCV infection among health 
professionals. The principal aims of Phase II (May 2008 to March 2011), backed by £43 
million of government investment, were "to diagnose HCV-infected people, particularly 
those who would most benefit from treatment, and to ensure that those infected receive 
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optimal treatment, care and support".(8) A key action was “to develop clinical services to 
increase numbers of persons undergoing therapy in Scotland” (Action 6). The extent to 
which the Action Plan has succeeded in this regard has not yet been extensively evaluated, 
but preliminary data indicate that the annual number of persons starting antiviral therapy 
has more than doubled between 2007/2008 (n = 468) and 2010/2011 (n = 1049).(9)  
Therefore, the main goals of the current study were (a) to examine the rate of, and 
factors associated with, attendance at a HCV specialist clinic following HCV diagnosis 
among chronically infected patients in Scotland; and (b) to examine the rate of, and factors 
associated with, initiation on HCV antiviral therapy among chronically infected patients 
who have attended a HCV specialist treatment clinic in Scotland. In addition to the principal 
aims stated above, further goals of the Action Plan included: increasing the numbers in 
specialist [hepatitis C] care among people who inject drugs (PWID); “improving HCV 
testing and referral activities by General Practitioners (GPs) and other community setting 
practitioners” (Action 10), increasing the numbers referred from prison, and “promoting the 
treatment of HCV-infected inmates in prisons” (Action 7).(8) Thus, we also assessed the 
effect of the implementation of the Phase II Action Plan on attendance at specialist clinics, 
specifically within these groups.  
 
METHODS 
Data sources and linkage 
The Scottish Hepatitis C Clinical Database, held at Health Protection Scotland (HPS), 
contains clinical follow-up data for HCV-infected patients attending specialist outpatient 
treatment clinics across Scotland (involving 16 clinics as at 2010; clinics were located in 
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departments of hepatology, gastroenterology, or infectious diseases). These data include the 
date of first clinic appointment, dates and outcomes of antiviral therapy course, detailed 
demographic, clinical, virological and histological data, and patient identifiers (date of birth, 
sex, surname Soundex (a consonant-only phonetic encoding), and forename initial). Data 
were restricted to individuals on the database on 31 December 2010; as at this date, the 
database contained records for 13,083 individuals with sufficient identifiers for linkage (i.e., 
complete data on date of birth, sex, surname Soundex, and forename initial). 
HPS also maintain the Scottish HCV Diagnosis database, which contains data on all 
new HCV antibody-positive diagnosed persons since testing commenced in 1991 (including 
stored serum back to 1985); laboratory detection of HCV antibody positivity is a requirement 
for inclusion.(10) This database contains information on dates and results of HCV antibody 
tests and first PCR result, source of referral, risk activitie(s) leading to infection, and limited 
identifying information (i.e., date of birth, sex, surname Soundex, forename initial, and 
postcode district of reference). As at 31 December 2009, this database comprised records for 
27,183 individuals;(11) of those persons with known risk factors, 89% were people who inject 
drugs (PWID). 
Records on the HCV Diagnosis database (to 31 December 2009) with sufficient 
identifiers for linkage (n=24,119; 88.7%) were deterministically linked to individuals on the 
HCV Clinical database (to 31 December 2010); a complete match on date of birth, sex, 
forename initial, and surname Soundex was required for a successful link (see Fig. 1). 
Data analysis 
Two principal analyses were conducted, with two outcome events defined accordingly 
to compare event rates in the periods before and after the launch of the HCV Action Plan: (a) 
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first clinic attendance among all chronically HCV-infected and diagnosed persons; (b) 
initiation on antiviral therapy among all chronically HCV-infected specialist clinic attendees. 
For analysis (a), the study population was first confined to those persons diagnosed 
with chronic HCV infection (antibody-positive and RNA-positive) in the period 1 January 
1996 to 31 December 2009, to allow for possible delays in data entry on the HCV Clinical 
database and to permit a minimum follow-up period of 12 months (n = 13,191; i.e., the sum 
of 4,381 non-linked and 8,810 linked records). The analysis period started in 1996 because 
PCR testing was routinely conducted by this time; however, 5,100 and 2,531 antibody-
positive persons had a negative first PCR test result or were not PCR tested, respectively. 
The study population was then further restricted by excluding the following NHS Health 
board (HB) areas: Grampian, Lothian, Orkney, Shetland, and Western Isles. The following 
HBs (representing the majority of the Scottish population) were included: Ayrshire & Arran, 
Borders, Dumfries & Galloway, Fife, Forth Valley, Greater Glasgow & Clyde, Highland, 
Lanarkshire, and Tayside (n=10,155; the sum of 3,364 non-linked and 6,792 linked records). 
The HB restriction was imposed because data on the HCV Clinical database was considered 
up-to-date (i.e. sufficiently complete to end 2010) for only the subset of specialist clinics 
located within the included HBs, at the time of analysis.  
Logistic regression modelling was used to examine the association between the 
outcome 'first clinic attendance within 12 months of HCV diagnosis' (if person had attended 
multiple clinics, the earliest date) and the covariates sex, age at diagnosis (grouped into <20 
years, 20-29, 30-39, 40-49, 50+ years), risk group (current/former PWID, non-PWID, not 
known), calendar period of HCV diagnosis (1996–1998, 1999–2001, 2002–2004, 2005–2007, 
2008–2009), source of HCV test referral (hospital, GP, drug/counselling clinic, prison, other), 
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and HB (GG & C, other). The period 2002-2004 was chosen as reference period so odds ratios 
(ORs) for the periods immediately preceding and immediately following the launch of the 
Phase II Action Plan could be informally compared. After removing 107 persons whose date 
of death was recorded before or within 30 days following HCV diagnosis date and 392 
persons whose date of HCV diagnosis occurred after their first clinical appointment, 9,747 
records remained for analysis. A sensitivity analysis was done to assess the influence of 
those cases where the date of first appointment was identical to the date of HCV diagnosis, 
but the date of HCV diagnosis was indicated to be more than 2 months earlier according to 
the Clinical database; for these cases, an earlier HCV diagnosis date may not have been 
identified due to the limited availability of identifiers for 12% of records on the HCV 
Diagnosis database (including those who tested anonymously at a genito-urinary medicine 
(GUM) clinic), or the individual may have been tested outwith Scotland. 
Because any extra effect of the Action Plan needs to be distinguished from a linear 
temporal trend in the log odds of first clinic attendance, a further analysis was conducted in 
which the variable period of HCV diagnosis was replaced by date of HCV diagnosis, fitted as a 
linear covariate (coded as decimal years), and the binary covariate era was added, defined as 
HCV diagnosis occurring pre-Phase II Action Plan (before 1 May 2008) or Phase II Action 
Plan (1 May 2008 to 31 December 2010). Tests for interaction between era and risk group, and 
era and referral source were also conducted, and separate multifactorial regression analyses 
were conducted for four subgroups of interest: PWID, referrals from GP, drug/counselling 
clinics, and prison settings. 
For analysis (b), the study population was restricted to linked chronic HCV-infected 
patients attending the following specialist clinics: Crosshouse Hospital, Dumfries & 
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Galloway Royal Infirmary, Ninewells Hospital, Gartnavel General Hospital, Glasgow Royal 
Infirmary, Kirkcaldy Hospital, Monklands Hospital, Raigmore Hospital, Southern General 
Hospital, Stirling Royal Infirmary, and Edinburgh Western General in the period 1 January 
1996 to 31 December 2009 (n = 5,786). The remaining clinics that contribute to the HCV 
Clinical database were excluded because data entry to end 2010 was either known to be 
incomplete or completeness could not be established. 
 After removing cases for whom the earliest date of initiation on antiviral therapy was 
recorded as occurring before the date of first clinic appointment (possibly because of being 
treated previously at a different clinic or moving to another HB area after treatment 
initiation; n = 46) and where date of death preceded first clinic appointment (n = 4; probable 
record-linkage errors), 5,736 records remained for analysis. 
Logistic regression modelling was used to examine the association between the 
outcome 'initiation on antiviral therapy within 12 months of first clinic attendance and the 
covariates: sex, age at first clinic (<20, 20-29, 30-39, 40-49, 50+ years), risk group 
(current/former PWID, non-PWID, not known), calendar period of first clinic (1996–1998, 
1999–2001, 2002–2004, 2005–2007, 2008–2009), and genotype (1, 2/3, 4/5, not known). A 
random intercept for clinic was included to model the correlation structure of the data 
(variation in treatment initiation rates across clinics); approximate 95% confidence intervals 
were calculated by assuming a normally-distributed standard error (SE). 
As done for outcome (a), a random-effects logistic regression analysis was conducted to 
ascertain if there was any extra effect of the Action Plan beyond a linear temporal trend in 
the log odds of treatment initiation within 12 months. In this analysis, the variable period of 
first clinic was replaced by date of first clinic (fitted as a linear covariate), and the binary 
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covariate era, defined as first clinic appointment occurring pre-Phase II Action Plan (before 1 
May 2008) or Phase II Action Plan (1 May 2008 to 31 December 2010). A test for interaction 
between risk group and era was also conducted. 
We expressed the clinical relevance of any effect attributable to the initiation of the 
Phase II Action plan in both analysis (a) and (b), by reporting absolute effects. These 
absolute effects were estimated as follows. First, the expected number of patients achieving 
the outcome at a single selected time point (two years after the initiation of Phase II) was 
calculated from the predicted probabilities derived from the fitted adjusted logistic 
regression model (including the era covariate) by applying these probabilities to a 
hypothetical cohort of 100 persons. Second, the expected number of patients achieving the 
outcome at the same time point in the counterfactual situation (i.e., had the intervention not 
taken place) was calculated from predicted probabilities derived from the fitted adjusted 
logistic regression model, but with era set to 0, and the probabilities were applied to a 100-
person hypothetical cohort. In the counterfactual situation, the probability of an outcome 
was derived from the temporal trend and the other covariates only. 
       
RESULTS 
First clinic attendance: demographic characteristics 
A detailed breakdown of the study population (n = 10,155; i.e., those persons diagnosed 
with chronic HCV infection 1996-2009, restricted set of HBs) according to key baseline 
characteristics is provided in Table 1. The median age at diagnosis was 33 years; 70% of the 
study population (restricted by HB) was male, 57% was PWID, and a hospital setting was 
the most common referral source (32%) for HCV testing. Overall, 54% (5,469/10,155 persons) 
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was determined to have ever attended a specialist clinic. The highest rates of ever-
attendance at a specialist clinic were observed in males (56%), non-PWID (59%), those 
diagnosed in 1996-1998 (56%), and in referrals from a GP (61%). 
Odds of first clinic attendance within 12 months of HCV diagnosis 
Thirty-four per cent (3,286/9,747) of the eligible study population (i.e., persons 
diagnosed with chronic HCV in the period 1996–2009, who were alive at 30 days following 
date of diagnosis and whose first clinic appointment, if any, was subsequent to date of 
diagnosis) attended a specialist hepatitis clinic within 12 months of being diagnosed. 
Seventeen per cent of those attending within 12 months had their first appointment within 
one month of HCV diagnosis; 13% had their first appointment within one week. The 
distribution of time to first appointment is shown separately for pre-Phase II and Phase II 
Action Plan eras in Fig. 2.  
 Multifactorial logistic regression analysis (Table 2) indicated that the adjusted odds 
were significantly greater for males (OR=1.2, 95% CI: 1.1-1.3), for those aged 20-29, 40-49 and 
50+ years, compared with 30-39 years (ORs = 1.2, 1.4, 1.3, respectively), and for referrals for 
testing from GP and drug/counselling clinic settings (ORs = 1.7, 1.6, respectively), compared 
with hospital referrals. The adjusted odds of first clinic attendance within 12 months were 
lower for persons aged <20 years at HCV diagnosis (OR = 0.7, 95% CI: 0.5-0.9), prison 
referrals (OR = 0.5, 95% CI: 0.4–0.6), and for persons with PWID or unknown risk (ORs = 0.5, 
95% CI: 0.4–0.6; 0.8, 0.7–1.0, respectively), compared with those with non-PWID risk. The 
adjusted odds of first clinic attendance were greater for the HCV diagnosis period 2008–2009 
(corresponding to the Action Plan Phase II era), compared with the reference diagnosis 
period 2002–2004 (OR = 1.5, 95% CI: 1.3–1.7), but there was an indication of a trend over time 
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in OR (ORs of 0.8, 0.9, 1.2 for HCV diagnosis periods 1999–2001, 2002–2004, and 2005–2007, 
respectively). 
The regression analysis replacing the covariate period of HCV diagnosis with date of 
diagnosis and era indicated that, after adjusting for a linear trend in the log odds of the 
outcome with date of diagnosis (OR = 1.05, 95% CI: 1.04-1.07), there was no significant effect 
associated with the Phase II compared with the pre-Phase II era (OR = 1.1, 95% CI: 0.9-1.3). 
Based on the predicted outcome probabilities for the average individual who is diagnosed 
with HCV two years following Phase II initiation (1 May 2010), an expected 43 out of 100 
hypothetical patients would first attend a specialist clinic within 12 months of this date. In 
the counterfactual situation of no intervention, an expected 41 out of 100 patients would 
have a first clinic attendance. 
Separate tests for interaction (see Appendix, Table A1) between era and risk group and 
between era and source of referral (adjusting for all other covariates) indicated that era 
effects did not statistically differ for PWID compared with non-PWID (interaction OR = 0.7, 
95% CI: 0.3 -1.4), for GP and prison referrals compared with hospital referrals (interaction 
ORs of 1.2, 95% CI: 0.8-1.6; 1.0, 95% CI: 0.5-1.9, respectively), but the era effect was 
significantly smaller for drug/counselling clinic referrals compared with hospital referrals 
(interaction OR = 0.5, 95% CI: 0.3-0.8). Regression analysis of the PWID subgroup only did 
not indicate an effect of era (OR = 0.9, 95% CI: 0.7-1.1). Subgroup analysis results for the three 
referral sources of interest were as follows: GP (OR = 1.4, 95% CI: 1.1-2.0), drug/counselling 
clinic (OR = 1.0, 95% CI: 0.6-1.7), and prison (OR = 0.4, 95% CI: 0.2-0.9), but should be 
interpreted with caution.  
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There were 334 cases where the date of first clinic attendance was identical to the date 
of HCV diagnosis, of which 194 had a date of HCV diagnosis recorded as more than two 
months earlier on  the Clinical database than the linked HCV diagnosis date. A sensitivity 
analysis was conducted to further explore this observation, by replacing the date of HCV 
diagnosis (from record-linkage) with the earlier date for these 194 cases. Logistic regression 
results were highly similar for both the linear temporal trend (OR = 1.06, approx. 95% CI: 
1.05-1.08) and the effect of era (OR = 1.1, approx. 95% CI: 0.9-1.3). 
Initiation on antiviral therapy: demographic characteristics 
Table 3 shows the baseline characteristics of the study population for outcome (b), 
initiation on antiviral therapy among clinic attendees (n = 5,736; i.e., chronic HCV-infected 
patients with first clinic attendance in the period 1996–2009). The majority were males (71%), 
67% were in the PWID risk group (81% of those with known risk group), and 43% had HCV 
genotype 2/3 (56% of those for whom genotype was known). The median age at start of 
follow-up was 35 years (IQR 29–42 years).  
Odds of initiation on antiviral therapy within 12 months of first clinic attendance 
Sixteen per cent (919/5736) of patients were initiated on antiviral treatment within 12 
months of their first attendance at a specialist clinic (Table 3).  Fig. 3 shows the cumulative 
probability of treatment initiation (within 12 months) for pre-Phase II and Phase II eras. 
 Random-effects logistic regression indicated that the odds of treatment initiation were 
significantly higher for those aged 40-49 and 55+ years compared with 30-39 year-olds (ORs 
of 1.4 and 1.4, respectively), and for patients with first clinic attendance in 1996-1998, 2005-
2007 and 2008-2009 (ORs of 2.1, 1.9, 3.8, respectively). Odds were significantly lower for 
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patients with genotype 1 or unknown genotype compared with genotype 2/3 (ORs of 0.7 and 
0.1, respectively), for 20-29 year olds (OR = 0.8), and for those with PWID (OR of 0.3). 
In the regression analysis replacing period of first clinic with date of  first clinic and era, the 
odds of treatment initiation, adjusted for the small linear temporal trend (OR = 1.05, approx. 
95% CI: 1.02-1.08) and the other covariates, were significantly greater in the Phase II 
compared with the pre-Phase II Action Plan era (OR = 1.9, approx. 95% CI: 1.5-2.4). Based on 
the predicted probabilities of an outcome for the average patient with first clinic attendance 
two years following Phase II initiation (1 May 2010), an expected 27 out of 100 hypothetical 
patients would be initiated on treatment within 12 months of their first clinic. In the 
counterfactual situation of no intervention, an expected 17 out of 100 patients would be 
initiated on antiviral therapy. 
The supplementary interaction test between era and risk group, adjusting for all other 
covariates, indicated that the era effect for PWID or NK risk groups did not differ from the 
era effect for non-PWID (interaction OR=1.3, 95% CI: 0.8-2.1; OR=1.1, 95% CI: 0.6-1.8, 
respectively) (see Appendix, Table A1). Analysis of the prison referrals subgroup did not 
indicate a significant effect of era, after adjustment for temporal trend and other covariates 
(OR = 1.6, 95% CI: 0.5-5.1). 
 
DISCUSSION 
Consistent with the goals of the Hepatitis C Action Plan for Scotland, the outcome 
'initiation on antiviral treatment' improved after commencement of Phase II. Although the 
odds of first attendance at a specialist clinic within 12 months among HCV-diagnosed 
persons and the odds of initiation on antiviral therapy among specialist clinic attendees 
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within 12 months were increased (1.5-fold and 3.8-fold, respectively in 2008-2009 compared 
with 2002-2004), an additional positive impact of the Action Plan could only be 
distinguished from the rising temporal trend over the study period for outcome (b); for 
outcome (a) the 95% confidence interval around the adjusted odds ratio for era overlapped 
1.0. 
Expression of effect sizes in absolute terms indicated that two years following the 
launch of Phase II, an additional 10 out of 100 clinic patients were predicted to be initiated 
on antiviral treatment within 12 months of their first clinic attendance, compared with the 
number expected in the counterfactual, no-intervention, scenario. The absolute effect size 
was much smaller for outcome (a); an extra 2 out of 100 HCV-diagnosed persons were 
predicted to attend their first clinic appointment within 12 months of diagnosis, compared 
with the number expected in the no-intervention scenario. 
With respect to outcome (a), first attendance at a specialist clinic within 12 months of 
HCV diagnosis, male sex, HCV diagnosis in 2005 or later (compared with 2002-2004), and 
referral from a GP or drug/counselling clinic had positive effects, whereas being younger 
than 20 years old and in the PWID risk category or having unknown risk were associated 
with lower odds of first clinic appointment. For GP referrals only, we observed a Phase II era 
effect (1.4-fold increased odds), beyond the effect of a rising temporal trend in a subgroup 
analysis. The <1 OR observed for prison referrals is due to adjustment for the stronger 
(OR=1.24) temporal trend (Table A1) observed for this subgroup; despite the increased 
proportion of prison-referred diagnosees attending their first clinic appointment within 12 
months in the Phase II era, this increase was small compared with the overall increase over 
the study period. 
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Outcome (b), initiation on antiviral therapy within 12 months of first clinic attendance, 
was positively associated with being 40 years of age or older, and first clinic attendance in 
the Phase II era. Reduced odds of treatment initiation were found for PWID, for those with 
genotype 1 or unknown genotype compared with genotype 2/3, and for younger patients 
(20-29 years). The OR of 0.10 for unknown genotype reflects the fact that all patients who are 
to start treatment will generally be tested for genotype, but few will be tested in the absence 
of an intention to treat. 
Evaluation of England's HCV Action Plan, launched in 2004, was consistent with an 
increase in HCV testing uptake and the proportion of positive diagnoses made, comparing 
post- with pre-2004 eras, but its impact on attendance at specialist clinics and uptake of 
treatment was not ascertained.(12) Antiviral treatment uptake for HCV infection has 
increased in a number of European countries(13) that have not yet implemented population-
level interventions as done in Scotland. In the study of Lettmeier et al., which was based on 
peginterferon sales over the period 2000-2006, there was, however, relative stability from 
2004 onwards in uptake among the European member states.(13) 
Scottish data indicate an increase in the rate of HCV testing and diagnosis from around 
2008, which possibly increased the odds of first clinic attendance. (9) It is therefore 
important to control for observed temporal trends in performance measures, as currently 
done.    
Our analysis was not designed to ascertain the specific factors underlying the 
improvement in treatment rates associated with the implementation of the HCV Action 
Plan. Barriers to treatment initiation, for example due to ongoing injecting drug use, alcohol 
abuse, and a chaotic lifestyle,(14) may have improved during the Action Plan. Our results 
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are consistent with injecting drug use as a barrier both to attending a specialist clinic 
following HCV diagnosis and to commencing antiviral therapy; for both outcome measures, 
the odds ratios associated with PWID or unknown risk activity categories compared with 
non-PWID were significantly lower than 1.0.  
Analysis (a) focuses on evaluating the effect of Phase II initiation on first clinic 
attendance among persons newly diagnosed with HCV; however, health boards may have 
sought to boost attendance in other ways (e.g., re-connecting with persons lost to follow-up). 
Similarly, analysis (b) focuses on patients newly attending clinics, and neglects efforts to re-
engage with past attendees. 
The strengths of our study include a large study population, and comprehensive data 
available on important covariates. There are also a number of limitations. First, our 
deterministic record-linkage approach relied on the availability of sufficient identifiers; 
records with incomplete identifiers on the HCV Clinical database may be associated with 
poor attendance, rather than inadequate recording of information on the database. However 
the number of records with insufficient identifiers was small (n = 127). Failure to find valid 
links may also be associated with the HCV testing setting; for example, persons diagnosed in 
a GUM clinic will have limited identifiers on the HCV diagnosis database. 
Second, our two outcome measures are not independent. Increasing the testing rates of 
patients who may already be showing early symptoms of liver damage could lead to an 
increased rate of referral to specialist clinics with the explicit goal of starting the patient on 
treatment; thus the observed improved treatment initiation rate in the Phase II era may be 
due, in part, to improved rates of diagnosis among those patients who are the most eligible 
for antiviral therapy. This is not an issue if one simply wishes to estimate rates of initiation 
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on treatment; however, any improvements cannot easily be attributed to performance of a 
single aspect of the Action Plan. In addition, we do not yet have data covering the whole of 
Phase II of the Action Plan (i.e., May 2008 through March 2011); the effect sizes associated 
with the Phase II era may change with addition of further data. 
Third, our method for distinguishing any intervention effect from a background 
increase over time fitted a linear trend over the entire study period; hence, the statistical test 
of the era regression coefficient, adjusting for temporal trend, is overly conservative. We had 
also considered using a variant of segmented regression analysis (15), which was developed 
for linear regression modelling of time-series data. Although the approach appeared suitable 
for evaluating the effect of an intervention in the current data, as it fits separate regression 
lines to the periods before and after the time of intervention, we concluded that there were 
insufficient data in the second segment (the Phase II era) to allow meaningful interpretation. 
This nation-level analysis reflects patient management pathways that exhibit substantial 
heterogeneity, in that the outcome measures for the various Health Boards differed at 
baseline, and specialist clinics responded to required changes associated with the HCV 
Action Plan at different rates; therefore, not all of the systems were functioning optimally 
during the Phase II period. 
Finally, the populations for both analyses are subject to selection bias. For example, for 
outcome (b), the study population can be considered a 'prevalent cohort' (i.e., patients are 
chronically infected with HCV at the start of follow-up, but with variation in time since 
acquiring infection). Because patients with more advanced disease progression may be 
referred for treatment (see related point above), inclusion in the study population is 
associated with the outcome. Thus, treatment rates within 12 months of first appointment, 
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although validly reflecting treatment rates in the study base (i.e., all patients attending 
specialist hepatitis care in Scotland), apply more to those patients with more advanced 
disease who may have a greater likelihood of being initiated on treatment relatively quickly. 
In addition, HCV testing/diagnosis was not as widespread in the pre-Phase II compared 
with the Phase II period;(9) thus the earlier period will tend to include patients with more 
advanced disease compared with the Phase II period, with a consequent higher likelihood of 
being referred for specialist care soon after a positive diagnosis is made. Analyses that 
exclude a fixed period of observation following first specialist clinic appointment could be 
conducted to address the former issue; the latter issue must be taken into account when 
interpreting the current findings. 
In summary, our analysis illustrates that the Hepatitis C Action Plan for Scotland has 
succeeded in increasing (over and above the temporal trend) the odds of initiating antiviral 
treatment among persons newly attending specialist clinics. The improvement observed 
over the study period in this key performance indicator is consistent with a positive impact 
of Scotland's Hepatitis C Action Plan on the management and care of chronically-infected 
individuals. Further monitoring and analysis is required to establish if there is any 
subsequent improvement in the odds of a first clinic attendance, and to confirm a sustained 
effect in the second outcome. This evaluation has substantial relevance to other countries 
looking to implement similar intervention plans. 
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Table 1. Characteristics of the study population (persons diagnosed with chronic HCV infection 
on the HCV Diagnosis database 1 January 1996 to 31 December 2009, with sufficient identifiers 
for linkage). N= 13,191.  
 
 HCV-diagnosed Restricted Ever attended a  
 in Scotland by HB* specialist clinic*  
  N (col%) N (col%) N (col%) row%‡  
 
All  13191 – 10155 – 5469 – 53.8% 
 
Sex Female 3967 (30.1) 3080 (30.3) 1523 (27.8) 49.4 
 Male 9224 (69.9) 7075 (69.7) 3946 (72.2) 55.8 
 
Risk group 
 PWID 7701 (58.4) 5789 (57.0) 3077 (56.3) 53.2 
 Non-PWID 807 (6.1) 608 (6.0) 358 (6.5) 58.9 
 NK 4683 (35.5) 3758 (37.0) 2034 (37.2) 54.1 
 
Period of HCV diagnosis 
 1996-1998 1965 (14.9) 1527 (15.0) 857 (15.7) 56.1 
 1999-2001 2953 (22.4) 2280 (22.5) 1211 (22.1) 53.1 
 2002-2004 3126 (23.7) 2432 (23.9) 1302 (23.8) 53.5 
 2005-2007 3017 (22.9) 2280 (22.5) 1206 (22.1) 52.9 
 2008-2009 2130 (16.1) 1636 (16.1) 893 (16.3) 54.6 
 
Source of referral 
 Hospital 4180 (31.7) 3254 (32.0) 1713 (31.3) 52.6 
 GP 3562 (27.0) 2305 (22.7) 1416 (25.9) 61.4 
 Drug/Counselling 919 (7.0) 812 (8.0) 480 (8.8) 59.1 
 Prison 977 (7.4) 783 (7.7) 384 (7.0) 49.0 
 Other/NK 3553 (26.9) 3001 (29.6) 1476 (27.0) 49.2 
 
Health board of residence 
 GGC 5498 (41.7) 5498 (54.1) 2987 (54.6) 54.3 
 Other 7693 (58.3) 4657 (45.9) 2482 (45.4) 53.3 
 
Median age at HCV diagnosis 
(IQR)  33 (27–41) 33 (27–40) 33 (27–41) 
 
Note. PWID = people who inject drugs; NK = not known; GGC = Greater Glasgow & Clyde; IQR = 
interquartile range. * Restricted to the following health boards for which associated clinical database 
records were deemed sufficiently up to date: Ayrshire & Arran, Borders, Forth Valley, Greater Glasgow & 






Table 2. Results of logistic regression analyses, where outcome is defined as first attendance at a 
specialist clinic within the 12 month period following HCV diagnosis (n = 9,747). 
 
    Unadjusted Adjusted Adjusted‡ 
 N  n (%)  OR  95% CI OR  95% CI OR  95% CI 
 
Sex Female 2950 935 (31.7) Ref.  Ref.  Ref. 
 Male 6797 2351 (34.6) 1.14 1.04-1.25 1.20 1.09–1.32 1.20 1.08–1.32 
 
Age at diagnosis 
 <20 years 260 53 (20.4) 0.67 0.49-0.91 0.68 0.51–0.91 0.65 0.48–0.90 
 20-29 3324 919 (27.6) 1.36 1.22-1.50 1.22 1.10–1.35   1.19 1.07–1.32  
 30-39 3535 1207 (34.1) Ref.  Ref.  Ref. 
 40-49 1705 731 (42.9) 1.96 1.74-2.22 1.43 1.26–1.62 1.42 1.25–1.62 
 50+ 916 376 (41.0) 1.82 1.57-2.12 1.30 1.11–1.52 1.24 1.06-1.46 
 
Risk group 
 PWID 5661 1647 (29.1) 0.54 0.45-0.64 0.54 0.45–0.64 0.53 0.44-0.64 
 Non-PWID 587 254 (43.3) Ref.  Ref.  Ref.  
 NK 3499 1385 (39.6) 0.86 0.72-1.03 0.81  0.68–0.98 0.81 0.67-0.97 
 
Source of referral 
 Hospital 3019 924 (30.6) Ref.  Ref.  Ref. 
 GP 2289 974 (42.6) 1.68 1.50-1.88 1.68 1.49-1.88 1.68 1.50-1.89 
 Drug/Counsel. clinic 798 309 (38.7) 1.43 1.22-1.68 1.57 1.33–1.86 1.58 1.33-1.87 
 Prison 770 124 (16.1) 0.44 0.35-0.54 0.49 0.40–0.61 0.50 0.40-0.61 
 Other/NK 2871 955 (33.3) 1.13 1.01-1.26 1.01 0.91-1.14 1.02 0.91-1.14 
 
Period of HCV diagnosis 
 1996-1998 1453 369 (25.4) 0.69 0.60-0.80 0.75 0.64–0.87  N/A 
 1999-2001 2227 616 (27.7) 0.78 0.68-0.88 0.86 0.75–0.98  N/A 
 2002-2004 2353 776 (33.0) Ref.  Ref.   N/A 
 2005-2007 2204 843 (38.2) 1.26 1.11-1.42 1.19 1.05–1.35  N/A 
 2008-2009 1510 682 (45.2) 1.67 1.67-1.47 1.50 1.31-1.73  N/A 
 
Date of HCV diagnosis (linear, per year)  1.08 1.07-1.09  N/A 1.05 1.04-1.07 
      
Era Pre-Phase II 8383 2679 (32.0) Ref.   N/A Ref. 
 Phase II 1364 607 (44.5) 1.71 1.52-1.92  N/A 1.07 (0.92-1.25) 
 
Note. N = number of persons; n = number of outcomes; OR = odds ratio; NK = not known; N/A = not 
applicable. ‡ Model replacing categorical covariate period of HCV diagnosis with linear date of HCV diagnosis 





Table 3. Results of univariate logistic regression and mutifactorial random-effects logistic 
regression analyses, where outcome is defined as initiation on antiviral therapy (n  = 919) within 
12 months of first attendance at a specialist clinic (n = 5,736). 
 
 Unadjusted   Adjusted  Adjusted‡ 
 N  n (%) OR   95% CI    OR   95% CI*   OR   95% CI* 
 
Sex Female 1648 272 (16.5) Ref.  Ref.  Ref. 
 Male 4088 647 (15.8) 0.95 0.81-1.11 1.02 0.85-1.21 1.03 0.87-1.22 
 
Age at first clinic 
 <20 years 82 8 (9.8) 0.69 0.33-1.45 0.83 0.37-1.86 0.72 0.33-1.57 
 20-29 1484 149 (10.0) 0.71 0.58-0.88 0.78 0.62-0.97 0.77 0.62-0.95 
 30-39 2297 311 (13.5) Ref.  Ref. 
 40-49 1329 296 (22.3) 1.83 1.53-2.18 1.38 1.14-1.68 1.39 1.15-1.68 
 50+ 544 155 (8.5) 2.54 2.04-3.17 1.42 1.11-1.83 1.40 1.10-1.79 
 
Risk group 
 PWID 3832 415 (10.8) 0.27 0.23-0.33 0.34 0.28-0.42 0.30 0.25-0.37 
 Non-PWID 877 270 (30.8) Ref.  Ref.  
 NK 1027 234 (22.8) 0.66 0.54-0.81 0.81 0.62-1.05 0.63 0.50-0.80 
 
Genotype 
 1 1866 323 (17.3) 0.73 0.63-0.85 0.74 0.62-0.87 0.73 0.62-0.85 
 2/3 2441 544 (22.3) Ref.  Ref.  
 4/5 33 14 (42.4) 2.57 1.28-5.16 1.80 0.85-3.82 1.70 0.82-3.53 
 NK 1396 38 (2.7) 0.10 0.07-0.14 0.10 0.07-0.15 0.12 0.08-0.16 
 
Period of first clinic  
 1996-1998 733 125 (17.1) 2.00 1.53-2.62 2.14 1.59-2.87  N/A 
 1999-2001 928 60 (6.5) 0.67 0.49-0.93 0.81 0.58-1.13  N/A 
 2002-2004 1288 120 (9.3) Ref.  Ref.   N/A 
 2005-2007 1570 270 (17.2) 2.02 1.61-2.54 1.94 1.52-2.47  N/A 
 2008-2009 1217 344 (28.3) 3.84 3.06-4.81 3.75 2.94-4.78  N/A 
 
Date of first clinic (linear, per year)   1.11 1.09-1.13  N/A 1.05 1.02-1.08 
 
Era Pre-Phase II 4707 631 (13.4) Ref.   N/A Ref. 
 Phase II 1029 288 (28.0) 2.51 2.14-2.95  N/A 1.88 1.51-2.35 
 
Note. N = number of persons; n = number of outcomes; OR = odds ratio; NK = not known; N/A = not 
applicable. * Approximate interval. ‡ Model replacing categorical covariate period of first clinic with linear 








Figure 1. Flow diagram for outcome (a). Grey boxes indicate study population for logistic 
regression analysis of odds of first specialist clinic appointment within 12 months of HCV 
diagnosis. 
 
Figure 2. Cumulative probability of first clinic attendance from date of HCV diagnosis, shown 
separately for the pre-Phase II Action Plan and Phase II Action Plan eras. 
 
Figure 3. Cumulative probability of initiation on antiviral therapy from date of first clinic 















Table A1. Results of interaction tests and subgroup analyses, using logistic regression, for 
outcome (a): first attendance at a specialist clinic within the 12 month period following HCV 
diagnosis, and for outcome (b): initiation on treatment within the 12 month period following 
first clinic attendance. 
 
 Pre-Phase II Phase II Interaction with Adj. era effect* Adj. time trend‡ 
 N n (%) N n (%)  era  OR  95% CI OR  95% CI OR  95% CI 
 
Outcome (a) 
All HCV-diagnosed 8383 2679 (32.0)1364 607 (44.5)  – – 1.41 1.08-1.84 1.05 1.04-1.07 
 
Risk group 
 PWID 5090 1424 (28.0) 571 223 (39.1) 0.67 0.33-1.36 0.86 0.69-1.08 1.08 1.06-1.10 
 Non-PWID 547 229 (41.9) 40 25 (62.5)    Ref.   – –  – – 
 NK 2746 1026 (37.4) 753 359 (47.7) 0.68 0.34-1.37  – –  – – 
 
Source of referral 
 Hospital 2715 788 (29.0) 304 136 (44.7)    Ref.   – –  – – 
 GP 1994 796 (39.9) 295 178 (60.3) 1.15 0.81-1.63 1.44 1.05-1.97 1.05 1.02-1.08 
 Drug/Counsel.  666 256 (38.4) 132 53 (40.2) 0.53 0.34-0.84 1.02 0.59-1.74 1.00 0.95-1.05 
  Clinic 
 Prison 704 106 (15.1) 66 18 (27.3) 1.00 0.53-1.87 0.42 0.20-0.92 1.24 1.15-1.34 
 Other/NK 2304 733 (31.8) 567 222 (39.2) 0.75 0.55-1.02  – –  – – 
 
Outcome (b) 
All patients 4707 631 (13.4)1029 288 (28.0)  – – 1.88 1.51-2.35 1.05 1.02-1.08 
 
Risk group 
 PWID 2550 178 (7.0) 503 105 (20.9) 1.28  0.79-2.06  – –  – – 
 Non-PWID 460 102 (22.2) 49 22 (44.9)     Ref.   – –  – – 
 NK 1697 351 (20.7) 477 161 (33.8) 1.06 0.62-1.81  – –  – – 
 
Prison referrals 290 17 (5.9) 61 14 (23.0)  – – 1.62 0.51-5.12 1.27 1.01-1.59 
 
Note. PWID = people who inject drugs; NK = not known. *Adjusted for all other covariates, including 
linear effects of date of HCV diagnosis. ‡ Effect of date of HCV diagnosis (OR per year), adjusted for all other 
covariates. 
 
 
 
 
 
